Longitudinal analysis of body weight trends in Hispanic adults during the SARS-CoV-2 virus pandemic (2019–2023): Insights from the N3C data
Journal of Clinical and Translational Science · 2026 · 10 (1)
DOI: 10.1017/cts.2026.10709 ↗Abstract
Abstract Background: SARS-CoV-2 virus pandemic, beginning in March 2020, disrupted dietary habits, lifestyles, and mental health, potentially exacerbating weight-related health differences. Existing evidence lacks a comprehensive nationwide longitudinal analysis of pandemic-related weight changes among Hispanic adults, particularly across demographic subgroups and comorbidities. Objective: To examine national longitudinal changes in body weight among U.S. Hispanic adults during SARS-CoV-2 virus pandemic (2019–2023). Methods: We utilized electronic health records(EHRs) from National Clinical Cohort Consortium (N3C) database (January 2019 to December 2023), covering Hispanic adults aged ≥21 years in 2019 with complete data records over these five years. Statistical approaches included paired/independent t -tests, ANOVA, repeated-measures ANOVA, McNemar-Bowker tests, and linear mixed models. Results: The study included 11,452 Hispanics aged 21–83 years; 65.1% were female; 83.5% were overweight/obese at baseline. Mean weight exhibited a peak-then-decline pattern, increasing from 80.6 kg (pre-pandemic) to 81.1 kg (2021), then decreasing to 80.8 kg (2023). This trajectory persisted across demographic and clinical subgroups. Younger adults (59 years) and those with obese II/III continued to lose weight. Differences in weight gain during 2019–2021 were seen in sex, race, smoking status, dietary environment, and SARS-CoV-2 virus infection. Chronic conditions showed divergent associations, with diabetes, stroke, cancer, kidney disease and dementia experienced weight loss. Conclusions: Hispanic adults exhibited shifts in weight patterns during SARS-CoV-2 virus pandemic, with significant differences observed across population subgroups. These findings highlight the need for targeted interventions that address the prolonged metabolic impacts of the pandemic in this population.
EUVIMED